{
    "clinical_study": {
        "@rank": "136270", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "Investigational product Tralokinumab"
            }, 
            {
                "arm_group_label": "High Dose", 
                "arm_group_type": "Experimental", 
                "description": "Investigational product Tralokinumab"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety and tolerability of multiple-doses of\n      tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis."
        }, 
        "brief_title": "D2212C00002 J-Phase II Study", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Pulmonary Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Pulmonary Fibrosis", 
                "Idiopathic Pulmonary Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase II, multicenter, blinded within cohort, dose-escalation study to evaluate\n      the safety and tolerability of two ascending doses of tralokinumab in Japanese patients aged\n      \u2265 50 years with mild to moderate Idiopathic Pulmonary Fibrosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of informed consent prior to any study specific procedures\n\n          -  Confirmed IPF diagnosis for \u2264 5 years prior to Visit 1 (screening).  Confirmation of\n             diagnosis of IPF\n\n          -  Mild to moderate IPF to include all of the following at Visit 1\n\n               1. FVC \u2265 50% and \u2264 90% predicted normal\n\n               2. Partial pressure of oxygen in arterial blood (PaO2) of \u2265 55 mmHg on room air, or\n                  oxygen saturation by pulse oximetry (SpO2) of \u2265 90% on room air at rest\n\n               3. Hemoglobin-corrected diffusion capacity for carbon monoxide (DLCO) \u2265 30% and \u2264\n                  90% predicted normal\n\n        Exclusion Criteria:\n\n          -  History of clinically significant environmental exposure (eg, domestic and\n             occupational) to a known cause of pulmonary fibrosis\n\n          -  Diagnosis of connective tissue disease or drug toxicity as the likely cause of the\n             interstitial disease\n\n          -  A suspected IPF exacerbation not fully resolved and treatment completed \u2264 14 days\n             prior to Visit 1\n\n          -  A suspected IPF exacerbation during the screening period\n\n          -  A FEV1/FVC ratio < 0.70 at the time of Visit 1 (postbronchodilator)\n\n          -  The extent of emphysema on the HRCT is greater than the extent of fibrosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036580", 
            "org_study_id": "D2212C00002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low Dose", 
                "description": "Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor", 
                "intervention_name": "tralokinumab cohort 1", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "High Dose", 
                "description": "Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor", 
                "intervention_name": "tralokinumab cohort 2", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Japan", 
            "Phase2", 
            "Safety", 
            "Tolerability", 
            "Idiopathic Pulmonary Fibrosis", 
            "IPF", 
            "CAT-354", 
            "Tralokinumab"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Himeji-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seto-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shibuya-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Astrazeneca Clinical Study information", 
            "phone": "800-236-9933"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Joseph M Parker, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "adverse events and serious adverse events using the Safety Population. Other variables used for the safety assessments include electrocardiogram, vital signs, and routine laboratory assessments. These variables as well as their changes from baseline will be summarized descriptively.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "From baseline to Week 48"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036580"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Serum tralokinumab concentration data will be summarized by treatment group.", 
                "measure": "Serum tralokinumab concentration data", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 48"
            }, 
            {
                "description": "The incidence rate of positive serum antibodies to tralokinumab will be reported.", 
                "measure": "Immunogenecity", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 48"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}